IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs ALT 803 (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2017 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 23 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 23 Oct 2017 Status changed from recruiting to active, no longer recruiting.